GeneDx Holdings

WGS

Market cap $3.4B

GeneDX CEO Katherine Stueland discusses how the company is using AI to help deliver "life-changing information." Want to hear the full interview?

GeneDX CEO Katherine Stueland talks about the impact of federal funding cuts to research programs. Want to hear the full interview?

Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map variants SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read technology, evaluating its performance on regions of the genome that traditional short-read technologies historically have not resolved. GeneDx's early results illustrate the ability of constellation to rapidly identify hard-to-detect variants implicated in rare disease.

GeneDx Holdings is transforming into a global genetic software leader, leveraging its vast database and recent Fabric Genomics acquisition. WGS achieved strong Q2 results: 49% revenue growth, 71% gross margin, positive cash flow, and raised full-year guidance, signaling accelerating adoption. The AAP's new recommendations and NIH funding position WGS for significant market expansion, with insurance coverage supporting sustainable, recurring revenue.

She started her career helping launch breakthrough treatments for HIV and cancer. Today, Katherine Stueland is leading GeneDx — a genetic testing company using genomic insights to diagnose rare diseases faster and more accurately than ever before.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced its involvement in the Sunshine Genetics Act, establishing the nation's first state-backed genomic newborn screening program.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced the Autism Partnership Program to expand access to exome and genome testing in partnership with Jaguar Gene Therapy.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced pioneering scientific contributions that will be presented at the American Society of Human Genetics (ASHG) Annual Meeting.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced it will release financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025.